Type 2 Diabetes Mellitus Therapeutics Market 2022 Type 2 Diabetes Mellitus Therapeutics Market 2022 | Page 2

DPP-4 inhibitors, SGLT-2 inhibitors, and insulin therapies. Nevertheless, significant unmet need
remains for products that can offer better glycemic control, as well as the prevention and cure of
diabetic complications, such as diabetic nephropathy, retinopathy, and cardiovascular disease.
Scope
The current South-East Asia T2DM market contains novel products, including Jardiance, a SGLT-2
inhibitor; Victoza, a GLP-1 receptor agonist; and Januvia, a DPP-4 inhibitor.
- What are the competitive advantages of the existing novel drugs?
With over 500 active pipeline molecules, most of the late-stage investigational drug candidates are
being evaluated, featuring improved dosing regimens and administration routes in comparison to
currently marketed products and combination therapies.
- Which classes of novel drugs are most prominent within the pipeline?
- Is there strong potential for the pipeline to address unmet needs within the T2DM market?
Analysis of clinical trials since 2006 identified that the failure rates of T2DM molecules were highest
in Phase III, at 49%, with the overall attrition rate for T2DM standing at 75%.
Read Sample report of this Category:
http://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare
- How do failure rates vary by product stage of development, molecule type, and mechanism of
action?
- How do other factors, such as average trial duration and trial size, influence the costs and risks
associated with product development?
Over the 2015-2022 forecast period, the South-East Asia T2DM therapeutics market is expected to
increase in value at a CAGR of 7.1%, from $1.7 billion to over $2.7 billion.
- Which markets make the most significant contribution to the current market size?
- What are the epidemiology trends in these markets?
- Will new market entrants lead to substantial changes in annual therapy costs?
- How will different treatment usage patterns impact growth in the eight assessed South-East Asia
markets?
Rising T2DM prevalence and the uptake of newer therapies will lead to significant market growth
over the forecast period, despite generic sales erosion resulting from patent expirations.
Follow Us: